Caricamento...
Eculizumab for atypical hemolytic-uremic syndrome in India: First report from India and the challenges faced
Much progress has been made in understanding the pathophysiology and treatment of atypical hemolytic uremic syndrome (aHUS). Plasma therapy is the mainstay of treatment for aHUS. The availability of the first effective anti-complement therapeutic agent, eculizumab, has dramatically changed the outlo...
Salvato in:
| Pubblicato in: | Indian J Nephrol |
|---|---|
| Autori principali: | , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Medknow Publications & Media Pvt Ltd
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5255992/ https://ncbi.nlm.nih.gov/pubmed/28182046 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0971-4065.179369 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|